Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.

Type 2 diabetes is characterized by impaired insulin secretion from pancreatic β-cells. Quantification of the islet area in addition to the insulin-positive area is important for detailed understanding of pancreatic islet histopathology. Here we show computerized automatic recognition of the islets of Langerhans as a novel high-throughput method to quantify islet histopathology. We utilized state-of-the-art tissue pattern recognition software to enable automatic recognition of islets, eliminating the need to laboriously trace islet borders by hand. After training by a histologist, the software successfully recognized even irregularly shaped islets with depleted insulin immunostaining, which were quite difficult to automatically recognize. The results from automated image analysis were highly correlated with those from manual image analysis. To establish whether this automated, rapid, and objective determination of islet area will facilitate studies of islet histopathology, we showed the beneficial effect of chronic exendin-4, a glucagon-like peptide-1 analog, treatment on islet histopathology in Zucker diabetic fatty (ZDF) rats. Automated image analysis provided qualitative and quantitative evidence that exendin-4 treatment ameliorated the loss of pancreatic insulin content and gave rise to islet hypertrophy. We also showed that glucagon-positive α-cell area was decreased significantly in ZDF rat islets with disorganized structure. This study is the first to demonstrate the utility of automatic quantification of digital images to study pancreatic islet histopathology. The proposed method will facilitate evaluations in preclinical drug efficacy studies as well as elucidation of the pathophysiology of diabetes.

[1]  P. Brubaker,et al.  Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice , 2002, Diabetologia.

[2]  M. Prentki,et al.  Islet beta cell failure in type 2 diabetes. , 2006, The Journal of clinical investigation.

[3]  Jae-Hyoung Cho,et al.  Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea , 2003 .

[4]  H. Jones,et al.  Variation in characteristics of islets of Langerhans in insulin‐resistant, diabetic and non‐diabetic‐rat strains , 2010, International journal of experimental pathology.

[5]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  B. Topp,et al.  Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. , 2001, Diabetes.

[7]  A. Fukunari,et al.  Expression of Vascular Endothelial Growth Factor (VEGF) Associated with Histopathological Changes in Rodent Models of Osteoarthritis , 2011, Journal of toxicologic pathology.

[8]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[9]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[10]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[11]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[12]  M. Stoffel,et al.  Evolution of β-Cell Dysfunction in the Male Zucker Diabetic Fatty Rat , 1995, Diabetes.

[13]  S. Yagihashi,et al.  Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients , 2002, Diabetologia.

[14]  Gloria Bueno,et al.  Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. , 2010, Folia histochemica et cytobiologica.

[15]  M. Prentki,et al.  Islet b cell failure in type 2 diabetes , 2006 .

[16]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[17]  J. Clark,et al.  The Diabetic Zucker Fatty Rat , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[18]  D. Drucker The biology of incretin hormones. , 2006, Cell Metabolism.

[19]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[20]  Keerthana Prasad,et al.  Image Analysis Tools for Evaluation of Microscopic Views of Immunohistochemically Stained Specimen in Medical Research–a Review , 2012, Journal of Medical Systems.

[21]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[22]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[23]  K. Polonsky,et al.  Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. , 1998, Diabetes.

[24]  B. Roysam,et al.  Digital Transplantation Pathology: Combining Whole Slide Imaging, Multiplex Staining and Automated Image Analysis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.